Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis

[1]  Eyton,et al.  A CONTROLLED TRIAL OF TWO NUCLEOSIDE ANALOGUES PLUS INDINAVIR IN PERSONS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND CD4 CELL COUNTS OF 200 PER CUBIC MILLIMETER OR LESS , 2000 .

[2]  I. Jacobs,et al.  p53 codon 72 polymorphism and risk of cervical cancer in UK , 1998, The Lancet.

[3]  J. Marx,et al.  Packed-cell volume in elite athletes , 1998, The Lancet.

[4]  Irene M. Leigh,et al.  Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.

[5]  M. Kazatchkine,et al.  Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease , 1998, AIDS.

[6]  J. Renner,et al.  Increased Rate of Fractures and Severe Kyphosis: Sequelae of Living into Adulthood with Cystic Fibrosis , 1998, Annals of Internal Medicine.

[7]  R. Yolken,et al.  Multivariate analysis of RNA levels from postmortem human brains as measured by three different methods of RT-PCR , 1997, Journal of Neuroscience Methods.

[8]  J. Lau,et al.  The impact of high-risk patients on the results of clinical trials. , 1997, Journal of clinical epidemiology.

[9]  E. Nestler,et al.  A molecular and cellular theory of depression. , 1997, Archives of general psychiatry.

[10]  G. Friedland,et al.  Adherence, compliance, and HAART. , 1997, AIDS clinical care.

[11]  D. Back,et al.  Protease Inhibitors in Patients with HIV Disease , 1997, Clinical pharmacokinetics.

[12]  C. Galán,et al.  Glutathione-S-Transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  R. Duman,et al.  Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[14]  H. Jürgens,et al.  Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism , 1996, British journal of haematology.

[15]  E. Nestler,et al.  Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens. , 1996, The Journal of pharmacology and experimental therapeutics.

[16]  P. Ridker,et al.  Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.

[17]  A R Jadad,et al.  Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. , 1995, Controlled clinical trials.

[18]  O. Hornstein,et al.  Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. , 1995, Arthritis and rheumatism.

[19]  S. Pillemer,et al.  Minocycline in Rheumatoid Arthritis: A 48-Week, Double-Blind, Placebo-Controlled Trial , 1995, Annals of Internal Medicine.

[20]  R. Birgander,et al.  Is p53 polymorphism maintained by natural selection? , 1994, Human heredity.

[21]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[22]  G. Tucker,et al.  The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). , 1994, Biochemical pharmacology.

[23]  L. Roberts,et al.  Survival following intentional massive overdose of 'Ecstasy'. , 1994, Journal of accident & emergency medicine.

[24]  D A Kessler,et al.  Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. , 1993, General hospital psychiatry.

[25]  R. Cowan,et al.  Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. , 1992, Thorax.

[26]  S. Dawling,et al.  Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") , 1992, The Lancet.

[27]  A. Silman,et al.  RELIABILITY OF SKIN INVOLVEMENT MEASURES IN SCLERODERMA , 1992 .

[28]  Gideon Koren,et al.  Determination of gestational cocaine exposure by hair analysis. , 1989 .

[29]  K R Westerterp,et al.  Study on Food Intake and Energy Expenditure During Extreme Sustained Exercise: The Tour de France , 1989, International journal of sports medicine.

[30]  W. Saris,et al.  Adequacy of vitamin supply under maximal sustained workloads: the Tour de France. , 1989, International journal for vitamin and nutrition research. Supplement = Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Supplement.

[31]  M. Boechat,et al.  Osteoporosis in cystic fibrosis. , 1988, The Journal of pediatrics.

[32]  D. Pim,et al.  Primary structure polymorphism at amino acid residue 72 of human p53 , 1987, Molecular and cellular biology.

[33]  K. Westerterp,et al.  Use of the doubly labeled water technique in humans during heavy sustained exercise. , 1986, Journal of applied physiology.

[34]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[35]  H. Krzywanek,et al.  On the Measurement of Spontaneous Platelet Aggregation. The Platelet Aggregation Test III. , 1976, Thrombosis and Haemostasis.